TOP - Daily
In a case-control study, regular use of 75 mg/day of aspirin— lower than the standard 81-mg dose of baby aspirin—significantly reduced the risk of developing colorectal cancer (CRC). The effect was evident after 1 year and increased with longer use.
The findings of this large population-based study are applicable to the general population, not just high-risk patients, according to the authors.
Patients with advanced cancer who die at home have greater quality of life (QOL) than patients who die in a hospital or intensive care unit. In addition, their caregivers experience less bereavement-related psychiatric illnesses, according to a study published online at the Journal of Clinical Oncology.
Methylphenidate (MPH), a drug used to treat attention deficit hyperactivity disorder in healthy children also has long-term benefits for childhood cancer survivors, a new study indicates.
After 12 months of treatment with MPH, children showed significant improvements on measures of attention, social skills, and behavior compared with a control group of children who did not receive MPH.
Adding two new biomarkers to a risk-prediction model allows enhanced identification of cancer patients at high or low risk of venous thromboembolism (VTE), according to a recent study published in Blood.
The US Food and Drug Administration (FDA) has approved a higher, more efficacious dose of fulvestrant (Faslodex, AstraZeneca) injection for treatment of metastatic breast cancer. The newly approved dose of 500 mg replaces the previously approved monthly dose of 250 mg for the treatment of hormone receptor–positive (HR+) metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Deaths from ovarian cancer could drop by as much as 50% in the next 20 years if surgeons remove the fallopian tubes of women undergoing a hysterectomy or tubal ligation, according to a team of gynecologic oncologists from Vancouver General Hospital and the British Columbia Cancer Agency.
Multivitamin use during and after adjuvant chemotherapy did not reduce the risk of cancer recurrence or mortality in patients with stage III colon cancer, according to recently released findings of Cancer and Leukemia Group B (CALGB) 89803. Multivitamin use, however, also did not impact patients’ health negatively.
Researchers have developed a tool for predicting individualized risk of local recurrence after breast-conserving surgery (BCS) in women with ductal carcinoma in situ (DCIS). The tool integrates 10 clinicopathologic variables to assist patients and their healthcare professionals decide among various treatment options with the goal of reducing over- and undertreatment of noninvasive breast cancer.
Radiation therapy after local surgical therapy should be considered in patients with adenoid cystic carcinoma (ACC) of the breast who are otherwise eligible for radiation therapy, concluded a group of researchers from the University of California-Davis.
For men with localized low-risk prostate cancer, there is no rush to decide on a treatment option, according to the National Prostate Cancer Register (NPCR) of Sweden Follow-up Study published online in the Journal of Urology. This suggestion is based on findings that after median follow-up of 8 years, men who underwent prompt radical prostatectomy had no significant difference in the presence of one of three adverse pathology features or in prostate cancer–specific mortality than men who deferred surgery for up to 19 months.